IDT Australia Limited provided earnings guidance for the second half of 2013. The Board of the company announced that it has received advice from a North American Pharmaceutical client that as a result of further FDA regulatory requirements there will be delays in the timing of its large development project till fiscal year 2014. Consequently, as a result of this delay, the Board expects that the financial result for second half of fiscal year 2013 will be similar to the financial result for first half of fiscal year 2013.